이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease

2026년 6월 15일 업데이트: Xuanwu Hospital, Beijing

Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease

The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:

Does adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?

Is the treatment combination safe for participants?

Researchers will compare two groups:

Group 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.

Group 2 (Control): Standard treatment alone.

Participants in this study will:

Be adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).

Be randomly assigned to one of the two treatment groups.

Take their assigned treatment for 6 months.

Attend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.

연구 개요

연구 유형

중재적

등록 (추정된)

300

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Aged 18 to 70 years (inclusive), male or female.
  2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.
  3. Glycated hemoglobin (HbA1c) < 12%, with recent fasting blood glucose < 7.0 mmol/L OR postprandial blood glucose < 10.0 mmol/L, and triglycerides < 1.7 mmol/L.
  4. Diagnosed with LEAD, meeting the following criteria:

    Rutherford Classification 2, 3, or 4.

    Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI > 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.

    Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.

  5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing "Practical Diagnostic Criteria for Blood Stasis Syndrome" and "Integrated Chinese and Western Medicine Peripheral Vascular Disease"):

    Main Symptom: Lower limb weakness, or feeling of heaviness/discomfort after prolonged walking.

    Secondary Symptoms: Shortness of breath/lassitude in speaking; dry mouth with desire to drink; scaly skin.

    Tongue & Pulse: Tongue with teeth marks, pale-purple with petechiae/ecchymosis; thin and choppy pulse.

    (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)

  6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.

Exclusion Criteria:

  1. Known bleeding disorders or history of intracranial hemorrhage.
  2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).
  3. Presence of active infection.
  4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).
  5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.
  6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR < 30 mL/min/1.73m²).
  7. History of malignancy (except cured basal cell carcinoma).
  8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.
  9. Planned lower limb revascularization or amputation.
  10. Concurrent or planned use of medicinal products containing Veratrum species.
  11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.
  12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).
  13. Patients with psychiatric disorders or judged to be uncooperative.
  14. Currently participating in another drug clinical trial or using therapies with similar purported effects.
  15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Standard Therapy and Hua Yu Wan Capsule

1. Standard Baseline Medication: Hua Yu Wan Capsule: 5g, taken orally two times daily. Treatment Duration: The combined regimen is administered continuously for 6 months (divided into four 6-week cycles).

2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments without receiving the study drug.

A modern preparation of the classic Traditional Chinese Medicine formula Bu Yang Huanwu Decoction. Each capsule contains 0.2g of the herbal extract.

Dosage and Route: 2 capsules, taken orally three times daily.

Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 12 months.
활성 비교기: Standard Therapy Alone
  1. Standard Baseline Medication:

    Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 6 months.

  2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments.
Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 12 months.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of new-onset ischemic rest pain or foot ulcer at 12 months of treatment.
기간: From enrollment to the end of treatment at 12 months

Ischemic Rest Pain: Persistent pain in the toes/forefoot at rest, typically nocturnal, worsened by elevation, relieved by dependency, often with pallor/coldness.

Foot Ulcer: Ischemic skin breakdown/tissue necrosis in pressure areas (toes, heel, sole), with well-defined edges, dry/necrotic base, poor perfusion, and absence of significant inflammation.

Assessment Method: Clinical evaluation by investigator at each scheduled visit. Confirmed by physical examination and documented photographically if applicable.

From enrollment to the end of treatment at 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Number of participants with investigator-confirmed new-onset ischemic rest pain or clinically confirmed ischemic foot ulcer at 12 months
기간: From enrollment to the end of treatment at 12 months
Composite primary outcome defined as the number of participants who develop either: (1) new-onset ischemic rest pain confirmed by investigator clinical assessment, or (2) ischemic foot ulcer confirmed by physical examination with photographic documentation when applicable, by Month 12.
From enrollment to the end of treatment at 12 months
Number of participants with major adverse cardiovascular and cerebrovascular events (MACCE)
기간: From enrollment to the end of treatment at 12 months
MACCE is defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
From enrollment to the end of treatment at 12 months
Number of participants hospitalized during the study
기간: From enrollment to the end of treatment at 12 months
Number of participants who require inpatient hospitalization for any cause during the study period, as confirmed by hospital admission records or investigator documentation. Repeated hospitalizations in the same participant will be counted once unless otherwise specified in the statistical analysis plan.
From enrollment to the end of treatment at 12 months
Number of participants who die during the study
기간: From enrollment to the end of treatment at 12 months
Number of participants who die from any cause during the study period, as confirmed by medical records, death certificates, hospital documentation, or investigator follow-up. Each participant will be counted once.
From enrollment to the end of treatment at 12 months
Change in ankle-brachial index(ABI) from baseline
기간: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in ankle-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in toe-brachial index (TBI) from baseline
기간: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in toe-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in intermittent claudication distance from baseline
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in intermittent claudication distance from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Rate of clinically driven lower-extremity arterial revascularization after treatment
기간: From enrollment to the end of treatment at 12 months
Rate of clinically driven lower-extremity arterial revascularization after treatment, including endovascular or open surgical revascularization: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months
Change in Vascular Quality of Life Questionnaire-6 score from baseline
기간: From enrollment to the end of treatment at 12 months
Change in Vascular Quality of Life Questionnaire-6 score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months
Change in Traditional Chinese Medicine syndrome score from baseline
기간: From enrollment to the end of treatment at 12 months
Change in Traditional Chinese Medicine syndrome score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months

기타 결과 측정

결과 측정
측정값 설명
기간
Number of participants with clinically significant bleeding events
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with bleeding events during the study. Unit of Measure: Participants
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal physical examination findings
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal findings on physical examination.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal hematology test results
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in hematology parameters, including white blood cell count, red blood cell count, hemoglobin, and platelet count.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal urinalysis results
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in urinalysis parameters, including urine white blood cells, urine red blood cells, urine glucose, and urine protein.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal liver function test results
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in liver function parameters, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, and gamma-glutamyl transferase.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal renal function test results
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in renal function parameters, including blood urea nitrogen or urea, and serum creatinine.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal coagulation test results
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in coagulation function parameters, including thrombin time, prothrombin time, activated partial thromboplastin time, international normalized ratio, and fibrinogen.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Body Temperature From Baseline
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in body temperature from baseline at each scheduled assessment. Unit of Measure: Degrees Celsius
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Pulse Rate From Baseline
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in pulse rate from baseline at each scheduled assessment. Unit of Measure: Beats per minute
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Respiratory Rate From Baseline
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in respiratory rate from baseline at each scheduled assessment. Unit of Measure: Breaths per minute
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Systolic Blood Pressure From Baseline
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in systolic blood pressure from baseline at each scheduled assessment. Unit of Measure: mmHg
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Diastolic Blood Pressure From Baseline
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in diastolic blood pressure from baseline at each scheduled assessment. Unit of Measure: mmHg
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal 12-lead electrocardiogram findings
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Measure Description: Number of participants with clinically significant abnormal findings on 12-lead electrocardiogram, as assessed by the investigator.

Unit of Measure: Participants

Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with positive pregnancy test results
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of female participants of childbearing potential with positive pregnancy test results during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Allergic Reactions
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with allergic reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Gastrointestinal Adverse Reactions
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with gastrointestinal adverse reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Nervous System Adverse Reactions
기간: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with nervous system adverse reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 1일

기본 완료 (추정된)

2028년 2월 1일

연구 완료 (추정된)

2029년 1월 1일

연구 등록 날짜

최초 제출

2026년 2월 11일

QC 기준을 충족하는 최초 제출

2026년 6월 15일

처음 게시됨 (실제)

2026년 6월 22일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 15일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다